BPC-157 vs GHR Peptide-6
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, BPC-157 or GHR Peptide-6?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between BPC-157 and GHR Peptide-6?
BPC-157 is a synthetic gastric pentadecapeptide with no GH-releasing activity; GHRP-6 is a growth hormone releasing peptide with dual GH secretagogue and cytoprotective properties - BPC-157 is purely tissue-protective while GHRP-6 has GH axis effects.
Evidence Comparison
BPC-157: 70+ rodent studies covering multiple tissue types, single research group (Sikiric, Zagreb). GHR-peptide-6 (GHRP-6): cytoprotective and wound healing studies primarily from Berlanga-Acosta et al. (Cuba), plus older GH secretagogue characterization studies. Both are limited by single-group dominance; BPC-157 has more total publications. Note: GHRP-6 is WADA prohibited.
Evidence Context Favoring BPC-157
Tissue repair research without GH axis involvement, or GI-specific protection studies.
Evidence Context Favoring GHR Peptide-6
Research combining GH secretagogue effects with cytoprotection, accepting limited Cuban group data and WADA prohibition status.
Side-by-Side Snapshot
| Evidence grade | BPC-157: Level B GHR Peptide-6: Level D |
|---|---|
| Research status | BPC-157: Phase 2 GHR Peptide-6: Preclinical |
| Primary category | BPC-157: Healing & Recovery GHR Peptide-6: Healing & Recovery |
| Cited studies | BPC-157: 10 GHR Peptide-6: 2 |